Basit öğe kaydını göster

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

dc.contributor.authorVillegas, A.
dc.contributor.authorPaz-Ares, L.
dc.contributor.authorSpira, A.
dc.contributor.authorRaben, D.
dc.contributor.authorPlanchard, D.
dc.contributor.authorCho, B. C.
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorDaniel, D.
dc.contributor.authorVicente, D.
dc.contributor.authorHui, R.
dc.contributor.authorMurakami, S.
dc.contributor.authorSpigel, D.
dc.contributor.authorSenan, S.
dc.contributor.authorLanger, C. J.
dc.contributor.authorPerez, B. A.
dc.contributor.authorBoothman, A-M
dc.contributor.authorBroadhurst, H.
dc.contributor.authorWadsworth, C.
dc.contributor.authorDennis, P. A.
dc.contributor.authorAntonia, S. J.
dc.contributor.authorFaivre-Finn, C.
dc.date.accessioned2021-03-06T12:49:49Z
dc.date.available2021-03-06T12:49:49Z
dc.date.issued2020
dc.identifier.citationPaz-Ares L., Spira A., Raben D., Planchard D., Cho B. C. , ÖZGÜROĞLU M., Daniel D., Villegas A., Vicente D., Hui R., et al., "Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial", ANNALS OF ONCOLOGY, cilt.31, ss.798-806, 2020
dc.identifier.issn0923-7534
dc.identifier.otherav_f5b6a60c-319f-4791-ab82-aef9bb9c76ef
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/161034
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2020.03.287
dc.description.abstractBackground: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectOnkoloji
dc.titleOutcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
dc.typeMakale
dc.relation.journalANNALS OF ONCOLOGY
dc.contributor.departmentCIBER - Centro de Investigacion Biomedica en Red , ,
dc.identifier.volume31
dc.identifier.issue6
dc.identifier.startpage798
dc.identifier.endpage806
dc.contributor.firstauthorID2283195


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster